Galectin-3 and Epithelial MUC1 Mucin-Interactions Supporting Cancer Development

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 22

PMID 37345016

Authors

Iwona Radziejewska

Affiliations

Soon will be listed here.

Abstract

Aberrant glycosylation of cell surface proteins is a very common feature of many cancers. One of the glycoproteins, which undergoes specific alterations in the glycosylation of tumor cells is epithelial MUC1 mucin, which is highly overexpressed in the malignant state. Such changes lead to the appearance of tumor associated carbohydrate antigens (TACAs) on MUC1, which are rarely seen in healthy cells. One of these structures is the Thomsen-Friedenreich disaccharide Galβ1-3GalNAc (T or TF antigen), which is typical for about 90% of cancers. It was revealed that increased expression of the T antigen has a big impact on promoting cancer progression and metastasis, among others, due to the interaction of this antigen with the β-galactose binding protein galectin-3 (Gal-3). In this review, we summarize current information about the interactions between the T antigen on MUC1 mucin and Gal-3, and their impact on cancer progression and metastasis.

Citing Articles

The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.

Dieli R, Lioy R, Crispo F, Cascelli N, Martinelli M, Lerose R Biomolecules. 2025; 15(2).

PMID: 40001578 PMC: 11853026. DOI: 10.3390/biom15020275.

Galectin-3 disrupts tight junctions of airway epithelial cell monolayers by inducing expression and release of matrix metalloproteinases upon influenza A infection.

Iqbal M, Feng C, Zong G, Wang L, Vasta G Glycobiology. 2024; 35(1).

PMID: 39569730 PMC: 11727335. DOI: 10.1093/glycob/cwae093.

Can Galectin-3 Be a Novel Biomarker in Chronic Lymphocytic Leukemia?.

Wos J, Szymanska A, Lehman N, Chocholska S, Zarobkiewicz M, Pozarowski P Cells. 2024; 13(1).

PMID: 38201234 PMC: 10778116. DOI: 10.3390/cells13010030.

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges.

Szymanowski W, Szymanowska A, Bielawska A, Lopez-Berestein G, Rodriguez-Aguayo C, Amero P Cancers (Basel). 2023; 15(21).

PMID: 37958473 PMC: 10647731. DOI: 10.3390/cancers15215300.

Tiliroside Combined with Anti-MUC1 Monoclonal Antibody as Promising Anti-Cancer Strategy in AGS Cancer Cells.

Radziejewska I, Supruniuk K, Jakimiuk K, Tomczyk M, Bielawska A, Galicka A Int J Mol Sci. 2023; 24(17).

PMID: 37685842 PMC: 10487805. DOI: 10.3390/ijms241713036.

References

Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y . Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2017; 41(2):599-614. PMC: 5752178. DOI: 10.3892/ijmm.2017.3311. View

Schjoldager K, Narimatsu Y, Joshi H, Clausen H . Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol. 2020; 21(12):729-749. DOI: 10.1038/s41580-020-00294-x. View

Mendez-Huergo S, Blidner A, Rabinovich G . Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis. Curr Opin Immunol. 2017; 45:8-15. DOI: 10.1016/j.coi.2016.12.003. View

Michel A, Nangia-Makker P, Raz A, Cloninger M . Lactose-functionalized dendrimers arbitrate the interaction of galectin-3/MUC1 mediated cancer cellular aggregation. Chembiochem. 2014; 15(14):2106-12. PMC: 4511962. DOI: 10.1002/cbic.201402134. View

Kaur S, Kumar S, Momi N, Sasson A, Batra S . Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013; 10(10):607-20. PMC: 3934431. DOI: 10.1038/nrgastro.2013.120. View

Ballester B, Milara J, Cortijo J . The role of mucin 1 in respiratory diseases. Eur Respir Rev. 2021; 30(159). PMC: 9488590. DOI: 10.1183/16000617.0149-2020. View

Vladoiu M, Labrie M, St-Pierre Y . Intracellular galectins in cancer cells: potential new targets for therapy (Review). Int J Oncol. 2014; 44(4):1001-14. DOI: 10.3892/ijo.2014.2267. View

Chen C, Duckworth C, Zhao Q, Pritchard D, Rhodes J, Yu L . Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res. 2013; 19(7):1693-704. PMC: 3618858. DOI: 10.1158/1078-0432.CCR-12-2940. View

Kufe D . MUC1-C in chronic inflammation and carcinogenesis; emergence as a target for cancer treatment. Carcinogenesis. 2020; 41(9):1173-1183. PMC: 7513951. DOI: 10.1093/carcin/bgaa082. View

10.

Wandall H, Blixt O, Tarp M, Pedersen J, Bennett E, Mandel U . Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010; 70(4):1306-13. PMC: 5538776. DOI: 10.1158/0008-5472.CAN-09-2893. View

11.

Merikhian P, Darvishi B, Jalili N, Esmailinejad M, Khatibi A, Kalbolandi S . Recombinant nanobody against MUC1 tandem repeats inhibits growth, invasion, metastasis, and vascularization of spontaneous mouse mammary tumors. Mol Oncol. 2021; 16(2):485-507. PMC: 8763658. DOI: 10.1002/1878-0261.13123. View

12.

Nakayama R, Kuroda J, Taniyama N, Yamamoto-Sugitani M, Wada S, Kiyota M . Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res. 2013; 38(1):103-8. DOI: 10.1016/j.leukres.2013.07.026. View

13.

Yu L, Andrews N, Zhao Q, McKean D, Williams J, Connor L . Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem. 2006; 282(1):773-81. DOI: 10.1074/jbc.M606862200. View

14.

Bhatia R, Gautam S, Cannon A, Thompson C, Hall B, Aithal A . Cancer-associated mucins: role in immune modulation and metastasis. Cancer Metastasis Rev. 2019; 38(1-2):223-236. PMC: 6614013. DOI: 10.1007/s10555-018-09775-0. View

15.

Karsten U, Goletz S . What controls the expression of the core-1 (Thomsen-Friedenreich) glycotope on tumor cells?. Biochemistry (Mosc). 2015; 80(7):801-7. DOI: 10.1134/S0006297915070019. View

16.

Apostolopoulos V, McKenzie I . Cellular Mucins: Targets for Immunotherapy. Crit Rev Immunol. 2018; 37(2-6):421-437. DOI: 10.1615/CritRevImmunol.v37.i2-6.110. View

17.

Xue H, Liu L, Zhao Z, Zhang Z, Guan Y, Cheng H . The N-terminal tail coordinates with carbohydrate recognition domain to mediate galectin-3 induced apoptosis in T cells. Oncotarget. 2017; 8(30):49824-49838. PMC: 5564810. DOI: 10.18632/oncotarget.17760. View

18.

Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S . MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol. 2007; 9(12):1419-27. PMC: 4209910. DOI: 10.1038/ncb1661. View

19.

Hong M, Weng I, Li F, Lin W, Liu F . Intracellular galectins sense cytosolically exposed glycans as danger and mediate cellular responses. J Biomed Sci. 2021; 28(1):16. PMC: 7931364. DOI: 10.1186/s12929-021-00713-x. View

20.

Hauselmann I, Borsig L . Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014; 4:28. PMC: 3923139. DOI: 10.3389/fonc.2014.00028. View